Reference health
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
70033-x/badge.svg){kind=icon}
22/22 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
2 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 22 checked references that resolve
resolves10.1126/science.2470152
Studies of the HER-2/
<i>neu</i>
Proto-Oncogene in Human Breast and Ovarian Cancer
resolves10.1126/science.3798106
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene
resolves10.1021/bi00139a003
Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments
resolves10.1056/NEJM200103153441101
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
resolves10.1200/JCO.2002.20.3.719
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of <i>HER2</i>-Overexpressing Metastatic Breast Cancer
resolves10.1200/JCO.2005.01.014
Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule
resolves10.1200/JCO.2005.04.173
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group
resolves10.1056/NEJMoa052122
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
resolves10.1093/annonc/12.suppl_1.S57
Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data
resolves10.1016/S0140-6736(07)60028-2
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
resolves10.1200/jco.2007.25.18_suppl.512
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer
resolves10.1200/JCO.2006.09.1611
Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial
resolves10.2307/2529712
Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
resolves10.1214/aos/1176350951
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
resolves10.1198/000313005X70371
Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator
resolves10.1158/0008-5472.SABCS-09-80
Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial.
resolves10.1200/jco.2007.25.18_suppl.lba513
Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)→paclitaxel (T) vs. AC→T with trastuzumab (H)
The 2 references without a DOI — listed, not checked
no DOI — not checkedSlamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: first interim analysis. 28th San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 7–10, 2005.
no DOI — not checkedSlamon D, Eiermann W, Robert N, et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2-amplified early breast cancer patients: third planned efficacy analysis. 32nd San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 9–13, 2009. Abstr 62.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/s1470-2045(11)70033-x"><img src="https://citestamp.com/citestamped/10.1016/s1470-2045(11)70033-x/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[70033-x/badge.svg)](https://citestamp.com/citestamped/10.1016/s1470-2045(11)70033-x)